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Abstract
Aim Parastomal hernia (PSH) is the most common
complication of an end-colostomy and about one-quar-
ter of patients need operative repair, which is often
unsuccessful. A randomized trial was carried out to
compare the results of using mesh or no mesh at the
time of formation of a colostomy with the clinical iden-
tification of PSH as the primary outcome.
Method In this two-centre randomized trial (Oslo
University Hospital and Sykehuset Innlandet Hospital
Trust, Norway), patients with rectal cancer undergoing
open pelvic surgery were randomized to receive a retro-
muscular synthetic mesh (study group, n = 32) or no
mesh (control group, n = 26) at the time of end-colost-
omy formation. Postoperative follow up was not
blinded and included clinical examination and routine
CT.
Results The median period of follow up was 40 (range:
84) months. There were no differences in demographic
variables or complications between the study and con-
trol groups. PSH developed in two patients of the study
group and in 12 of the control group [OR = 0.04 (95%
CI: 0.01–0.30) and hazard ratio 0.134 (95% CI:
0.030–0.603); P < 0.001]. The number needed to treat
to avoid one PSH was 2.5 patients. CT demonstrated
an increase over time in the size of the fascial orifice in
patients with PSH without mesh prophylaxis, in con-
trast to a stable size in patients with mesh and in the
control patients who did not develop PSH.
Conclusion The retromuscular insertion of synthetic
mesh at the time of formation of an end-colostomy
reduced the risk of PSH.
Keywords Parastomal hernia, mesh prophylaxis, ran-
domized controlled trial, end-colostomy
What does this paper add to the literature?
The study confirms that the incidence of parastomal
hernia at the site of an end-colostomy is reduced by the
implantation of synthetic mesh at the time of construc-
tion. It has added substantially to the accumulated evi-
dence of the value of mesh insertion in the prevention
of PSH and thus enhances the knowledge base of the
surgical community.
Introduction
The incidence of stoma creation in a general population
is 4–6/10 000 and the prevalence is 15–20/10 000
[1–3]. Most permanent stomas are created in an elective
setting. Complication rates after creation of end-colost-
omy are reported to range from 21% to 70% [4,5].
Commonly they include stomal prolapse, stenosis and
skin problems around the stoma. Fistula formation and
stoma retraction are less frequent. The most common
delayed complication is development of a parastomal
hernia (PSH), which is observed clinically in up to 48%
of patients with an end-colostomy [6] and in up to 78%
when assessed by CT [7]. More than 25% of patients
with clinical PSH require surgical repair [8]. This has a
high recurrence rate and the best strategy is therefore
prevention. There is no agreement on whether it is bet-
ter to bring the colon directly through the rectus abdo-
minis muscle or lateral to it, or whether the terminal
colonic segment should be sited retroperitoneally
[9,10]. Use of a prophylactic mesh in stoma creation
Correspondence to: Jan Roland Lambrecht, Sykehuset Innlandet Hospital Trust,
Surgical department, Kyrre Greppsgate 11, N-2819 Gjøvik, Norway.
E-mail: jan@lambrecht.no
Colorectal Disease ª 2015 The Association of Coloproctology of Great Britain and Ireland. 17, O191–O197 O191
Original article doi:10.1111/codi.13065
has been reported to reduce the incidence of PSH with-
out increase in complications [11–14]. The data avail-
able regarding long-term outcome are, however,
insufficient to determine the benefit of mesh insertion
and its impact on clinical practice.
The aim of the present study was to compare the use
of mesh with no mesh insertion at the time of forma-
tion of an end-colostomy. A randomized clinical trial
(RCT) was designed, with PSH determined by clinical
assessment as the primary outcome. Secondary out-
comes included stoma complications and re-operation
rates. In addition, the size of the stoma orifice in the
anterior abdominal wall and the radiological diagnosis
of PSH were determined retrospectively by CT.
Method
Study design
The study was a multicentre design with blinded random-
ization of patients to two groups, namely mesh prophy-
laxis (study group) and no mesh prophylaxis (control
group), in the creation of an end-colostomy. A 90%
power estimation with a = 0.05, based on a published
study [15], suggested a sample size of 50 patients. After
adjustment for expected mortality, a sample size of 60
was planned. Before the start of the study, the computer-
ized randomization process was carried out by the project
leader in blocks of six and sealed in numbered envelopes.
The patients were consigned to the next sequential envel-
ope after inclusion by the indiscriminately allocated oper-
ating surgeons. Patients having abdominoperineal
excision (APE) with curative intent for low rectal cancer
and those having surgery with curative intent for recur-
rent rectal cancer or other pelvic cancer resulting in an
end-colostomy were included. Patients having palliative
resections were excluded. Two surgical centres in Norway
participated, including a specialized research centre (Oslo
University Hospital, Norwegian Radium Hospital) and a
district teaching hospital (Sykehuset Innlandet Hospital
Trust, Gjøvik). Written informed consent was manda-
tory. The trial was approved by the Regional Committee
for Medical and Research Ethics South East Norway
(REK number: S-07203a). Data handling was approved
by the Norwegian Data Inspectorate (NSD number: 07/
4222), and the study was reported to ClinicalTrials.gov
before inclusion was initiated (ClinicalTrials.gov number:
NTC00496418).
Patients and surgical procedures
Sixty patients were included from September 2007 to
September 2011. All were White people and 25% were
female. The mean age was 64 years. Three patients
underwent pelvic exenteration, nine Hartmann’s opera-
tion and 48 APE. Thirty-two patients were randomly
allocated to the study group and 28 were randomly
allocated to the control group, but two patients in the
control group were excluded from the trial as palliative
status was identified during surgery. The remaining 26
patients in the control group underwent an APE. The
stoma trephine was made through the rectus abdominis
muscle. A large-pore, low-weight polypropylene mesh,
measuring 10 9 10 cm (Prolite Ultra; Atrium/Maquet
Getinge Group, G€oteborg, Sweden), was used in 28
patients and a Parietene Light (Covidien/Medtronic,
Minneapolis, Minnesota, USA) was used in four
patients. The mesh was trimmed to fit in the space
between the rectus muscle and the posterior rectus
sheath, most often 7 or 8 cm wide. A cruciform inci-
sion, 2 9 2 cm was made in the centre of the mesh to
allow passage of the colon. The lateral corners of the
mesh were sutured to the rectus sheath with a single
stitch (Polysorb 2-0 (Covidien/Medtronic) and medi-
ally included in the continuous Maxon 0 (Covidien/
Medtronic) or PDS 0 (Ethicon, Somerville, New Jersey,
USA) main wound fascial closure [16]. In the control
group, no mesh was used.
Follow up
Patients underwent clinical assessment and CT scan of
the chest, abdomen and pelvis as part of the cancer fol-
low up at 6-month intervals for the first 2 years and
thereafter annually for 4 years. This regime was inter-
rupted in the event of incurable cancer recurrence or
death. The stoma was assessed by inspection and palpa-
tion with the patient in the supine and erect positions
and during a Valsalva manoeuvre. A bulge associated
with the stoma was defined as a clinical PSH and was
graded similarly to the classification of the European
Hernia Society (EHS) [17], as follows: Type I, PSH
≤ 5 cm without concomitant main wound incisional
hernia (cIH); Type II, PSH ≤ 5 cm with cIH; Type III,
PSH > 5 cm without cIH; and Type IV, PSH > 5 cm
with cIH. CT assessment of PSH was not part of the
original protocol, but the size of the orifice in the ante-
rior abdominal wall was measured from the last CT
examination. The orifice was measured in transverse and
sagittal planes and its area was calculated using the for-
mula for an ellipse. The CT scans were evaluated for
PSH by an experienced radiologist (LJ) who was una-
ware of the randomization category. CT-assessed PSH
was categorized according to the classification of
Moreno–Matias [18], as follows: Grade Ia, bowel form-
ing the stoma with a peritoneal sac < 5 cm; Grade Ib,
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bowel forming the stoma with a peritoneal sac > 5 cm;
Grade II, the presence of omentum alongside the stoma
in the dorsal rectus sheath; or Grade III, a protruding
bowel loop other than forming the stoma.
Statistical analysis
Fisher’s exact test was used for binomial data, and para-
metric or nonparametric tests were used for continuous
variables and in multiple logistic regression models. The
adjusted odds of PSH were estimated for mesh prophy-
laxis and adjusted for body mass index (BMI)
(≤ 25 kg/m2; > 25 and ≤ 30 kg/m2; or > 30 kg/m2),
age (≤ 60 years, > 60 and ≤ 70 years; or > 70 years),
the size of the stoma aperture at the time of the first
postoperative CT examination (≤ 500, > 500 and
≤ 750 mm2; or > 750 mm2), acquired other incisional
hernia (IH), chronic obstructive pulmonary disease
(COPD) and gender. The cumulative occurrence of
PSH was determined by Kaplan–Meier and Cox regres-
sion analysis. The significance level was set at five per
cent in all tests. ORs with 95% CI were determined,
with the control group as reference.
Results
Clinical parameters
There were no differences in the patient characteristics
between the 32 patients in the study group and the 26 in
the control group (Table 1). One patient in the study
group received steroid therapy and did not develop PSH
or complications. The median follow-up was 36 (range:
81) months in the study group and 48 (range: 71)
months in the control group (Table 2). Twelve and six
patients in the study and control groups, respectively,
developed recurrence of cancer and subsequently died.
Stoma-related complications
There were no stoma-site infections, stoma retraction or
fistula formation. Two patients in the study group had
a stomal stenosis in the immediate postoperative period.
Both needed intervention; this involved digital disten-
tion of the stoma orifice in one patient and enlargement
of the aperture of the mesh in the other. One patient
without mesh had stomal necrosis and needed surgical
revision (Table 1).
Clinical detection of PSH
Two (6%) patients with mesh developed PSH compared
with 12 (46%) in the control group (P < 0.001,
Table 2). The adjusted OR for PSH with mesh vs no
mesh was 0.032 (95% CI: 0.003–0.333, Table 3).
Adjustment for hernia in previous history and COPD was
omitted in the analysis because of the low prevalence and
even distribution of these between the groups. The pres-
ence of an IH of the main abdominal wound did not
influence the results and without this adjustment a more
precise estimate was revealed (OR = 0.043; 95% CI:
0.006–0.304). In contingency table analysis the relative
risk for PSH with mesh was 0.14 (95% CI: 0.02–0.55)
and the number of mesh implants needed to avoid one
PSH was 2.5 (95% CI: 1.9–6.9).
The two patients with PSH in the study group died
shortly after 3 years of follow-up. They both had a BMI
in the normal range (23 and 24 kg/m2) and were in
their early 60s. They developed no other complications
and did not have hernia in their previous history. In
adjusted analysis of the patients who were alive at
3 years, the reduction of the risk of PSH was main-
tained (OR = 0.019; 95% CI: 0.001–0.352). The sur-
vival analysis demonstrated a significant difference
between the groups (Kaplan–Meier analysis, log–rank
test: P = 0.001). In adjusted Cox regression analysis the
hazard ratio for PSH with mesh prophylaxis was 0.134
(95% CI: 0.030–0.603, P = 0.009) (Fig. 1). The risk of
developing PSH continued over time in the control
group, whereas this was not the case in the study
group: in the study group, both instances of PSH
occurred after 3 and 12 months; in contrast, eight of
the 12 instances of PSH in the control group occurred
later than 18 months after surgery.
Factors associated with PSH and clinical detection of
PSH
Eleven of the 12 patients with PSH in the control group
and the two patients with PSH in the study group were
men (P = 0.330), but the estimate for gender as an
adjustment factor was imprecise. In multinomial regres-
sion analysis of male patients, the OR for developing
PSH with mesh in comparison with no mesh was 0.036
(95% CI: 0.003–0.390). A postoperative IH of the main
abdominal wound occurred in eight (31%) patients in the
control group, concurrently with PSH in seven. In con-
trast, five (16%) patients in the study group developed an
IH without PSH (P = 0.213). Development of IH was
associated with PSH (OR = 10.11; 95% CI: 1.22–83.55;
P = 0.032) and is a complicating factor in stoma care and
PSH repair, as exemplified by the EHS classification [17].
BMI was associated with development of PSH in the con-
trol group (OR = 1.31; 95% CI: 1.00–1.72; P = 0.050).
Applying the CT measurements of the aperture in the
anterior abdominal wall, the clinical distribution corre-
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sponding to the EHS classification was as follows: Type I
(n = 3), Type II (n = 6), Type III (n = 2) and Type IV
(n = 1) in the control group; and Type I (n = 2) in the
study group.
CT evaluation of the stomal aperture
The mean interval from stoma creation to the first post-
operative CT scan was 4 months in both groups and at
this time the median size of the stoma aperture was
similar in the groups (Table 2). After controlling for
age, a large aperture size at the first CT scan was associ-
ated with a higher BMI in the study group (P = 0.038)
but not in the control group (P = 0.495). At the last
CT examination, the median aperture size was
688 mm2 in the control group and unaltered, at
494 mm2, in the study group (P = 0.024), at a mean
respective interval of 33  23 months and 28
 18 months between CT studies. This significant
increase of aperture size in the control group was highly
associated with the development of PSH. BMI was asso-
ciated with a change in the area of the aperture in the
control group (increase of 37 mm2 per BMI point
increase, P = 0.011) and was correlated with the size of
the stoma orifice at the last CT scan in both groups
(P = 0.015, study group and 0.024, control group).
Association between the CT scan and clinical
detection of PSH
In the control group, CT failed to detect four clinical
PSHs, one of which was in need of surgical repair, and
three patients in the control group with a PSH diag-
nosed by CT did not have clinical evidence of PSH.
PSH was detected in eight patients by both methods.
In the study group, six patients with a nonclinical PSH
were diagnosed by CT. One of these had abdominal
surgery 2 years after creation of the colostomy and no
PSH was found. The two clinically detected PSHs in
the study group were both also diagnosed by CT. There
was therefore poor agreement between the clinical and
CT diagnosis of PSH, but when these methods of diag-
nosis were combined, there was a difference in the rate
of PSH (25% vs 58%; P = 0.016, Fisher’s exact test).
Discussion
This randomized trial suggests that a synthetic mesh
placed in the retromuscular space at the time of fashion-
ing an end-colostomy protects against PSH. The risk of
mesh-related complications was low and in keeping with
previously published results originally described by
Bayer et al. [19], but now confirmed with the use of a
modern large-pore mesh. The significant difference in
the development of PSH in this study is in accordance
with previously reported results from four RCTs
[12,13,20,21] and five observational studies [14,22–
25]. Two of the RCTs, with 27 patients in each arm,
employed a partially degradable synthetic mesh placed
in the retromuscular space [13,21]. One of the other
RCTs used a similar technique with a biological mesh
but it included only 10 patients in each arm [20], and
in the fourth RCT, with 18 and 16 patients in the
experimental and control groups, respectively, the mesh
was placed intraperitoneally [12]. Three systematic
reviews [26–28] and one meta-analysis [29] evaluating
the first three RCTs concluded that retromuscular mesh
prophylaxis has short-term efficacy without increased
morbidity, but further studies were needed before a rec-
ommendation could be made. The results of the present
study substantiate the conclusion regarding efficacy and
further suggest that this strategy also provides longer-
term protection against PSH, in agreement with
another report of the long-term outcome [30].
Although recently described techniques of laparo-
scopic repair of PSH appear to be promising [25,31], sec-
ondary repair still has a failure rate of up to 46% and
Table 1 Characteristics of patients having (study group) and
not having (control group) mesh prophylaxis against paras-
tomal herniation during the formation of an end-colostomy.
Variable
Mesh
(n = 32)
No mesh
(n = 26) P
Patient data
Age (years) 64  4.0 63  4.1 0.729*
ASA (0–E) 1.7  13 1.8  10 0.603*
BMI (kg/m2) 24.6  0.6 25.5  0.8 0.531*
Female 10 (31) 5 (19) 0.374†
Pulmonary
disease
3 (9) 2 (8) 1.000†
Heart disease 12 (38) 9 (35) 1.000†
Previous hernia 2 (6) 3 (12) 0.648†
Colostomy complications
Stenosis 2 (6) 0 0.497†
Necrosis 0 1 (4) 0.448†
Prolapse 0 1 (4) 0.448†
Dehiscence 0 1 (4) 0.448†
Skin problem 1 (3) 2 (8) 0.582†
Total
complications
3 (9) 5 (21) 0.446†
Reoperations 2 (6) 1 (4) 1.000†
Values are given as mean  SD or n (%)..
*Independent variables t-test.
†Fisher’s exact test.
ASA, American Association of Anaesthesiologists’ physical
score; BMI, body mass index.
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carries a risk of infection in up to 17% of cases [32]. A
reduction in the incidence of PSH by mesh prophylaxis
will thus have an important impact on the quality of life
of stoma patients. The number needed to treat (NNT) to
prevent one PSH repair within the study period was 13
(P = 0.24, CI: 7, ∞), approaching results that can be
derived from an analogous study [13] . As survival after
treatment for rectal cancer is increasing, PSH will also
increase [6,33] and this will lead to an even lower stoma
NNT with mesh to avert PSH repair. In summary, pre-
vention of PSH by mesh insertion should reduce the
complications resulting from development of PSH and
the need for a PSH repair (which has a high chance of fail-
ing), demonstrating that this is an advance in the treat-
ment of patients who require a permanent colostomy.
With laparoscopic procedures becoming more com-
mon, alternative techniques to open retromuscular mesh
placement will be required. For these situations, the
intraperitoneal slit [25] or modified Sugarbaker [12]
methods for prophylactic mesh placement have been pro-
posed. A simpler procedure resembling the open retro-
muscular mesh insertion technique has been described, in
which a retromuscular mesh insertion is made through
the stoma site before bringing the colon through the ori-
fice in the abdominal wall [34]. An evaluation of syn-
thetic and biological mesh was made by Fleshman et al.
[35]. They found no difference in the rate of PSH
between the groups, but almost 40% of stomas were
ileostomies, PSH rates for separate stoma types were not
reported and the PSH rate in the control group was
exceptionally low, at just 13% at 24 months.
Poor correlation between the clinical and CT detec-
tion of PSH was found in the present study. If clinically
diagnosed PSH were to be the reference, CT detected
nine false positives and four false negatives, suggesting
that detection of a hernia sac without a Grade III PSH
category is difficult and that a CT aimed mainly to detect
recurrence is unreliable in distinguishing omentum from
mesocolic or epiploic fat, whereas a dedicated CT scan,
Table 2 Prophylaxis against parastomal hernia formation by insertion of a mesh during fashioning of an end-colostomy.
Characteristic
Mesh (study group)
(n = 32)
No mesh (control
group) (n = 26) P OR (95% CI)
Developed PSH 2 (6) 12 (46) < 0.001* 0.08 (0.01–0.45)
Developed IH 5 (16) 8 (31) 0.213a* 0.42 (0.10–1.72)
Developed cIH 0/32 7/26 (30) 0.002* 0.00 (0.00–0.53)
Developed cIH, PSH patients 0/2 7/12 (58) 0.462* 0.00 (0.00–4.49)
Died during follow up 12 (38) 6 (23) 0.268* 2.00 (0.55–7.51)
Follow up (months) 36 (6–87) 48 (3–74) 0.254†
Stoma orifice size
At first CT (mm2) 511 (236–1018) 499 (283–1244) 0.896‡
At last CT (mm2) 494 (198–1144) 688 (207–1824) 0.024‡
Change (mm2) 18 (452 to 320)
(P = 0.644§)
114 (189 to 899)
(P = 0.003§)
0.001‡
Values are given as n (%), n/n total (%) or median (minimum–maximum).
*Fisher’s exact test/contingency table analysis.
†Mann–Whitney U-test.
‡Independent-samples t-test on log10 transformation of the variables.
§Related-samples sign test.
cIH, concomitant incisional hernia; IH, incisional hernia, main abdominal wound; PSH, parastomal hernia.
Table 3 Multinomial logistic regression of mesh prophylaxis
against parastomal hernia after the formation of an end-colost-
omy
Variable
Parastomal hernia
All patients 3-year survivors
Mesh
prophylaxis*
0.032 (0.003–0.333) 0.018 (0.001–0.452)
Mesh
prophylaxis†
0.043 (0.006–0.304) 0.019 (0.001–0.352)
Mesh
prophylaxis*
(male patients)
0.034 (0.003–0.433) 0.036 (0.002–0.732)
Mesh
prophylaxis†
(male patients)
0.036 (0.003–0.390) 0.040 (0.002–0.683)
Values are adjusted ORs (with 95% Wald CIs) for clinical
parastomal hernia formation compared with no mesh insertion.
*Adjusted for age, body mass index (BMI), stoma aperture size
at first CT and development of other incisional herniation.
†Adjusted for age, BMI and stoma aperture size at first CT
(control).
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namely one that is focussed on detecting PSH, has previ-
ously been shown to correspond well with the clinical
findings [36]. Furthermore, the clinical significance of a
diagnosis by a nondedicated CT scan is indeterminate [7]
and clinical evaluation and patient-reported symptoms
seem more relevant. Interestingly, the median size of the
fascial orifice increased over time in patients without a
mesh, but mostly in patients who developed PSH. Stabi-
lization of the fascial opening possibly explains the pro-
phylactic effect of the mesh against PSH.
In accordance with previously published studies, the
present randomized trial dramatically reduced the rate of
PSH formation without increasing complications. CT-
assessed fascial orifice size was markedly associated with
PSH, and stabilization by the mesh is possibly a crucial
factor for the prevention of PSH. Patients scheduled for a
permanent colostomy should be considered for a prophy-
lactic mesh procedure to reduce the incidence of PSH.
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